Diagnosis and management of intrahepatic cholestasis of pregnancy: current practices and future directions

Intrahepatic cholestasis of pregnancy (ICP) is a reversible, pregnancy-specific liver disorder characterized by impaired bile flow and maternal hypercholanemia, classically presenting in the late second or third trimester with pruritus on normal skin and resolving after delivery. Global prevalence is up to ~2%, with higher rates reported from India (≈3–4.5%), reflecting genetic (e.g., ABCB4/ABCB11/ATP8B1 variants), hormonal, and environmental contributions. Diagnosis is based on clinical and biochemical criteria, with pruritus and elevated non-fasting total bile acids confirming cholestasis and stratifying fetal risk. Adverse perinatal outcomes (preterm birth, meconium-stained liquor, fetal asphyxia, neonatal respiratory distress, and stillbirth) track with TBA in a concentration-dependent manner, with risk increasing ~1–2% for each µmol/l above 40 µmol/l in severe disease and rising markedly at ≥100 µmol/l. Management prioritizes maternal symptom relief and bile-acid reduction with ursodeoxycholic acid (UDCA- the first drug approved by CDSCO based on an Indian Phase 3 trial; 10–15 mg/kg/day, titrated), while cholestyramine may be considered for refractory cases; vitamin K is reserved for prolonged cholestasis or coagulopathy. Because conventional fetal surveillance (CTG/ultrasound) does not reliably avert sudden compromise, outcome modification relies on timely, TBA-guided delivery (typically by 40 weeks for 19–39 µmol/l, 38–39 weeks for 40–99 µmol/l, and 35–36 weeks for ≥100 µmol/l), balancing stillbirth prevention against prematurity; antenatal corticosteroids are used solely for lung maturation. Postpartum reassessment confirms resolution and guides counseling on recurrence risk and the use of progestin-only contraception. Emerging work on transporter biology, biomarkers, and optimized second-line therapy is poised to refine individualized, bile-acid–guided care and further improve perinatal outcomes.